Karman: Why I'm Upgrading To Buy After A 68% Drop

Karman Holdings was upgraded to Buy after its shares fell 68%, supported by Q2 organic growth of 24%, a record $1.3 billion backlog, and increased 2026 revenue and EBITDA guidance. Improved visibility into 2027 revenue supports a favorable multi-year demand outlook. However, weak free cash flow, elevated leverage, unresolved internal-control deficiencies, and a recent CFO transition remain material execution and governance risks.

Analysis

The key rerating question is not backlog growth but conversion quality. KRMN’s equity will remain constrained until investors can underwrite that incremental revenue converts into cash after working-capital needs, program start-up costs, and interest expense; absent this, raised EBITDA guidance may be treated as low-quality earnings and the multiple discount versus defense/aerospace peers can persist. The CFO change and internal-control remediation also raise the probability that reported quarterly performance carries a governance haircut until at least two clean reporting cycles.

Near term, the setup is technically favorable only if the post-selloff shareholder base has reset: further evidence of book-to-bill strength or a clean next earnings print could drive a sharp relief rally over 1-3 months given the depressed valuation. Over 6-18 months, the more important upside comes from backlog converting without inventory or receivables consuming cash, allowing deleveraging and a lower cost of capital. Conversely, a single program delay, cash-flow guide miss, covenant-related concern, or further control weakness would matter disproportionately because leverage removes flexibility to absorb execution variance.

Consensus may be too focused on the headline revenue visibility and too willing to annualize strong organic growth. A large backlog is economically less valuable when its mix has fixed-price exposure, milestone timing risk, or elevated working-capital intensity; the missing diligence is backlog margin, advance-payment terms, customer concentration, net-leverage trajectory, and expected remediation completion date. Until those data improve, this is a catalyst-driven special situation rather than a core aerospace/defense compounder.

Key Decisions for Investors

• Keep KRMN on a conditional long watchlist rather than chase the upgrade: initiate only after the next report confirms positive free-cash-flow conversion and no new control deficiencies. Target a 1-3 month tactical position sized small, with a stop/reassessment on EBITDA guidance reduction, negative FCF materially below plan, or net leverage rising sequentially.
• For a cleaner expression of the underlying aerospace/defense demand cycle, favor a paired structure: long ITA or XAR versus short KRMN only if KRMN rallies materially ahead of verified cash conversion. The thesis is that KRMN’s governance and balance-sheet discount should widen relative to diversified peers if execution disappoints.
• Monitor quarterly receivables, inventory, capex, cash interest, and backlog-to-revenue conversion as the decisive data set. Two consecutive quarters of improving operating cash flow, declining leverage, and completed control remediation would falsify the bearish quality-of-earnings view and justify upgrading KRMN to a 6-18 month long.
• Avoid long-dated upside options until liquidity and implied volatility are assessed; the relevant catalyst window is the next earnings release and control-remediation update, not a broad multi-year demand narrative.